open access
The type of distribution of PD-L1 positive immune cells and PD-L1 expression in tumor cells correlate with the development of non-classical differentiation in urinary bladder cancer
- Department of Tumour Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, Izabeli Romanowskiej 2, 85-796 Bydgoszcz, Poland
- Department of Clinical Pathomorphology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
- Department of Tumour Pathology and Pathomorphology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
open access
Abstract
Background: The basic diagnostic tool of urinary bladder cancer is the histopathological assessment.
However, it is insufficient to accurately predict the progression of this disease. There is a need to look
for new prognostic factors that will make the therapeutic process more effective. The aim of this study is
to evaluate the effect of activation of a PD1 – PD-L1 immune checkpoint in immune effector cells (IECs)
and tumor cells, on the development of malignancy in the form of non-classic differentiation in urinary
bladder cancer.
Materials and methods: 110 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent radical
cystectomy/cystoprostatectomy between 2011 and 2014 were included in the study. Tumor advancement
(pT stage), grade (G), as well as, non-classic differentiation frequency and number were evaluated pathologically.
In each case, the area of the tumor containing PD-L1+ IECs was analyzed. The distribution of
PD-L1+ immune effector cells within the tumor was also assessed as dispersed or aggregated.
Results: The frequency of non-classic differentiation was significantly lower in urothelial bladder cancer
tumors with a dispersed pattern of distribution of PD-L1+ IECs. A correlation between the extent of PD-L1
expression in tumor cells and the non-classic differentiation number in UBC was identified.
Conclusions: The distribution of cells expressing the immune checkpoint biomarker PD-L1 constitutes a
new prognostic factor and may play a key role in the selection of individualized immunotherapy. In addition,
the evaluation of non-classic differentiation in the tumor may complement the assessment of PD-L1
expression due to its capacity to characterize the current malignant potential of the tumor, whereas the
assessment of extent and distribution of PD-L1+ in tumor-associated immune cells indicates the functional
status of the immune system.
Abstract
Background: The basic diagnostic tool of urinary bladder cancer is the histopathological assessment.
However, it is insufficient to accurately predict the progression of this disease. There is a need to look
for new prognostic factors that will make the therapeutic process more effective. The aim of this study is
to evaluate the effect of activation of a PD1 – PD-L1 immune checkpoint in immune effector cells (IECs)
and tumor cells, on the development of malignancy in the form of non-classic differentiation in urinary
bladder cancer.
Materials and methods: 110 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent radical
cystectomy/cystoprostatectomy between 2011 and 2014 were included in the study. Tumor advancement
(pT stage), grade (G), as well as, non-classic differentiation frequency and number were evaluated pathologically.
In each case, the area of the tumor containing PD-L1+ IECs was analyzed. The distribution of
PD-L1+ immune effector cells within the tumor was also assessed as dispersed or aggregated.
Results: The frequency of non-classic differentiation was significantly lower in urothelial bladder cancer
tumors with a dispersed pattern of distribution of PD-L1+ IECs. A correlation between the extent of PD-L1
expression in tumor cells and the non-classic differentiation number in UBC was identified.
Conclusions: The distribution of cells expressing the immune checkpoint biomarker PD-L1 constitutes a
new prognostic factor and may play a key role in the selection of individualized immunotherapy. In addition,
the evaluation of non-classic differentiation in the tumor may complement the assessment of PD-L1
expression due to its capacity to characterize the current malignant potential of the tumor, whereas the
assessment of extent and distribution of PD-L1+ in tumor-associated immune cells indicates the functional
status of the immune system.
Keywords
PD-L1; urothelial bladder cancer; tumor microenvironment; immune cell, NDN, immune effector cells, IEC, immunological control point distribution, ICPD
Title
The type of distribution of PD-L1 positive immune cells and PD-L1 expression in tumor cells correlate with the development of non-classical differentiation in urinary bladder cancer
Journal
Issue
Article type
Original article
Pages
136-141
Published online
2019-05-24
Page views
479
Article views/downloads
644
DOI
Bibliographic record
Medical Research Journal 2019;4(3):136-141.
Keywords
PD-L1
urothelial bladder cancer
tumor microenvironment
immune cell
NDN
immune effector cells
IEC
immunological control point distribution
ICPD
Authors
Mateusz Matusiak
Jarosław Starzyński
Jakub Jóźwicki
Jakub Dzierżawski
Jan Misiak
Wojciech Jóźwicki
- Bellmunt J, Orsola A, Leow JJ, et al. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii40–iii48.
- Crundwell M. Pathology and genetics of tumours of the urinary system and male genital organs. BJU International. 2004; 94(4): 675–675.
- Jozwicki W, Domaniewski J, Skok Z, et al. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. Urology. 2005; 66(5): 1122–1126.
- Domanowska E, Jozwicki W, Domaniewski J, et al. Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol. 2007; 38(5): 741–746.
- Jóźwicki W, Brożyna AA, Siekiera J, et al. Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget. 2016; 7(10): 11450–11462.
- Jóźwicki W, Brożyna AA, Siekiera J, et al. Expression of RCAS1 correlates with urothelial bladder cancer malignancy. Int J Mol Sci. 2015; 16(2): 3783–3803.
- Jóźwicki W, Brożyna AA, Siekiera J. Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci. 2014; 15(9): 16069–16082.
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348(6230): 56–61.
- Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7): 813–824.
- Szabados B, van Dijk N, Tang YZ, et al. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol. 2018; 73(2): 149–152.
- Jóźwicki W, Skok Z, Brożyna A, et al. Urological Oncology Prognostic and diagnostic implications of histological differentiation in invasive urothelial cell carcinoma of the bladder: variant or non-classic differentiation number. Central European Journal of Urology. 2010; 63: 112–116.
- Jóźwicki W. VENTANA PD-L1 (SP142) - principles of pathomorphological evaluation in urinary bladder cancer. ; 2017.
- Kim SP, Frank I, Cheville JC, et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012; 188(2): 405–409.
- Huang Y, Zhang SD, McCrudden C, et al. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep. 2015; 33(6): 3075–3084.
- Tzeng A, Diaz-Montero CM, Rayman PA, et al. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Target Oncol. 2018; 13(5): 599–609.
- Pichler R, Fritz J, Lackner F, et al. Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. Clin Genitourin Cancer. 2018; 16(5): e1015–e1024.
- Driver BR, Miller RA, Miller T, et al. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Arch Pathol Lab Med. 2017; 141(11): 1529–1532.
- El Jabbour T, Ross JS, Sheehan CE, et al. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J Clin Pathol. 2018; 71(1): 46–51.
- Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015; 85(3): 703.e1–703.e6.
- Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031): 1909–1920.
- Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528): 558–562.
- Markowitz GJ, Havel LS, Crowley MJp, et al. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight. 2018; 3(13).
- Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21(1): 24–33.
- Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11): 1015–1026.
- Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017; 18(2): 212–220.
- Zhang X, Shi X, Li J, et al. PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine. J Cancer. 2018; 9(23): 4374–4381.
- de Jong JJ, Stoop H, Nieboer D, et al. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology. 2018; 73(6): 983–989.
- He J, Hu Y, Hu M, et al. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep. 2015; 5: 13110.